<?xml version="1.0" encoding="UTF-8"?>
<p>Mesenchymal stem cells (MSC) have immunomodulatory properties because they can inhibit T cell and macrophage activation and induce the formation of regulatory T cell and anti-inflammatory macrophages (
 <xref rid="B121" ref-type="bibr">121</xref>, 
 <xref rid="B122" ref-type="bibr">122</xref>). Their anti-inflammatory activity inhibits the secretion of IL-1, TNFα, IL-6, IL-12, and IFN-γ and promotes IL-10 and VEGF secretion which prevents lung tissue damage (
 <xref rid="B121" ref-type="bibr">121</xref>, 
 <xref rid="B123" ref-type="bibr">123</xref>). There is a pre-proof clinical trial that demonstrated the efficacy of the MSC treatment in patients with ARDS secondary to Influenza A (H7N9) infection (
 <xref rid="B124" ref-type="bibr">124</xref>). Several ongoing clinical trials are testing the mesenchymal stem cells therapy against SARS-CoV-2.
</p>
